Altimmune (ALT)

• Market cap: $296M
• 1 day: -4.70%
• 5 days: -14.32%
• 1 month: -5.68%
• 3 months: -30.48%
• 6 months: -47.86%
• Year to date: -48.66%
• 1 year: -42.25%
• 5 years: -85.99%
• 10 years: -99.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 59

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

31% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $10.3M

2% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 52

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

4% less funds holding

Funds holding: 180 [Q4 2024] → 173 (-7) [Q1 2025]

7.34% less ownership

Funds ownership: 56.87% [Q4 2024] → 49.53% (-7.34%) [Q1 2025]

10% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 29

35% less capital invested

Capital invested by funds: $292M [Q4 2024] → $191M (-$101M) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 229% upside
• Avg. target: $13.50 270% upside
• High target: $15 311% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Jonathan Wolleben	311% upside $15	Market Outperform Maintained	10 Jul 2025
HC Wainwright & Co. Patrick Trucchio	229% upside $12	Buy Reiterated	27 Jun 2025